1-156624121-A-G
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_021817.3(HAPLN2):c.400A>G(p.Ile134Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I134L) has been classified as Uncertain significance.
Frequency
Consequence
NM_021817.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
HAPLN2 | NM_021817.3 | c.400A>G | p.Ile134Val | missense_variant | 4/7 | ENST00000255039.6 | |
HAPLN2 | XM_011509853.3 | c.400A>G | p.Ile134Val | missense_variant | 4/7 | ||
HAPLN2 | XM_017002020.2 | c.400A>G | p.Ile134Val | missense_variant | 5/8 | ||
HAPLN2 | XM_047427123.1 | c.533A>G | p.His178Arg | missense_variant | 5/5 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
HAPLN2 | ENST00000255039.6 | c.400A>G | p.Ile134Val | missense_variant | 4/7 | 1 | NM_021817.3 | P1 | |
HAPLN2 | ENST00000456112.1 | c.400A>G | p.Ile134Val | missense_variant | 4/5 | 5 | |||
HAPLN2 | ENST00000494218.1 | n.58A>G | non_coding_transcript_exon_variant | 1/3 | 2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 20, 2023 | The c.400A>G (p.I134V) alteration is located in exon 4 (coding exon 2) of the HAPLN2 gene. This alteration results from a A to G substitution at nucleotide position 400, causing the isoleucine (I) at amino acid position 134 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.